Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma
Stopped early · Phase 1/Phase 2
Conditions studied: Pancreatic Cancer
In brief
The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.
Key facts
- Study ID
- NCT00587132
- Run by
- Mayo Clinic
- People needed
- 4
- Starts
- 2006-11-01
- Expected to finish
- 2012-02-01
- Last updated by the study team
- 2013-06-24
Who can join
Age: 35 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Persons 50 years or older with recently diagnosed diabetes (within 2 years), with at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum CA 19-9, or those undergoing EUS with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening ; OR
- Persons 35 years old or older with familial pancreatic cancer with 2 or more first degree relatives with pancreatic cancer; OR
- Persons 35 years old or older with Peutz-Jeghers syndrome; OR
- Persons 35 years old or older with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.
You may not qualify if…
- Persons with contraindication to iodinated contrast
- Allergy to iodinated contrast
- Renal insufficiency (serum creatinine > 1.5 mg/dl)
- Patients with contraindication to ionizing radiation
- Pregnancy
- Patients with previous pancreatic surgery
- Contraindication to secretin
- Allergy to secretin
- Acute pancreatitis
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.